Ipratropium Bromide

New England Journal of Medicine

Volumn 319, Issue 8, 1988, Pages 486-494

  Oates, John A ^a   Wood, Alastair J j ^a   Gross, Nicholas J ^b  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b HINES VA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; FENOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL; ATROPINE DERIVATIVE; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT;

ASTHMA; BRONCHITIS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; EMPHYSEMA; HUMAN; INHALATIONAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE;

ATROPINE DERIVATIVES; BRONCHODILATOR AGENTS; HUMAN; IPRATROPIUM; LUNG DISEASES, OBSTRUCTIVE; PARASYMPATHOLYTICS;

EID: 0024297084     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198808253190806     Document Type: Review

References (119)

1. Schmittling G, Black RR, Stern TL, Clinton C. Practice locations of family practice residency graduates. J Med Educ 1981; 56: 709–16.
2. Mattson DE, Stehr DE, Will RE. Evaluation of a program designed to produce rural physicians. J Med Educ 1973; 48: 323–31.
3. Rabinowitz HK. A program to recruit and educate medical students to practice family medicine in underserved areas. JAMA 1983; 249: 1038–41.
4. Herman MW, Veloski J. Family medicine and primary care: trends and student characteristics. J Med Educ 1977; 52: 99–106.
5. Veloski J, Herman MW, Gonnella JS, Zeleznik C, Kellow WF. Relationships between performance in medical school and first postgraduate year. J Med Educ 1979; 54: 909–16.
6. Herman MW, Veloski JJ. Premedical training, personal characteristics and performance in medical school. Med Educ 1981; 15: 363–7.
7. Schmittling G, Clinton C, Tsou C. Entry of U.S. medical school graduates into family practice residencies: 1983–84. Fam Med 1986; 18: 296–300.
8. Tudor CG, Beran RL. Trends in medical school applicants and matriculants, 1978–1986. Washington, D.C.: Association of American Medical Colleges, 1987.
9. Willoughby TL, Arnold L, Calkins V. Personal characteristics and achievements of medical students from urban and nonurban areas. J Med Educ 1981; 56: 717–26.
10. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975; 51: Suppl 7: 13–20.
11. Roy CS, Brown G. On bronchial contraction. J Physiol (Lond) 1885; 6: xxi–xxv.
12. Nadel JA, Barnes PJ. Autonomic regulation of the airways. Annu Rev Med 1984; 35: 451–67.
13. Widdicombe J. Reflex control of tracheobronchial smooth muscle in experimental and human asthma. In: Lichtenstein LM, Austen KF, eds. Asthma: physiology, immunopharmacology, and treatment: second international symposium. New York: Academic Press, 1977:225–31.
14. Richardson JB. Nerve supply to the lungs. Am Rev Respir Dis 1979; 119: 785–802.
15. Gold WM. The role of the parasympathetic nervous system in airways disease. Postgrad Med J 1975; 51: Suppl 7: 53–62.
16. Nadel JA, Barnes PJ, Holtzman MJ. Autonomic factors in hyperreactivity of airway smooth muscle. In: Macklem PT, Mead J, eds. Handbook of physiology. Vol. 3. Part 2. Section 3. The respiratory system. Bethesda, Md.: American Physiological Society, 1986:693–702.
17. Barnes PJ, Basbaum CB, Nael JA. Autoradiographic localization of autonomic receptors in airway smooth muscle: marked differences between large and small airways. Am Rev Respir Dis 1983; 127: 758–62.
18. Ingram RH Jr, Wellman JJ, McFadden ER Jr, Mead J. Relative contributions of large and small airways to flow limitation in normal subjects before and after atropine and isoproterenol. J Clin Invest 1977; 59: 696–703.
19. Hensley MJ, O'Cain CF, McFadden ER Jr, Ingram RH Jr. Distribution of bronchodilatation in normal subjects: beta agonist versus atropine. J Appl Physiol 1978; 45: 778–82.
20. Ashutosh K, Mead G, Dickey JC Jr, Berman P. Kuppinger M. Density dependence of expiratory flow and bronchodilator response in asthma. Chest 1980; 77: 68–75.
21. McFadden ER Jr, Ingram RH Jr, Haynes RL, Wellman JJ. Predominant site of flow limitation and mechanisms of postexertional asthma. J Appl Physiol 1977; 42: 746–52.
22. Partridge MR, Saunders KB. Site of action of ipratropium bromide and clinical and physiological determinants of response in patients with asthma. Thorax 1981; 36: 530–3.
23. Weiss JW, McFadden ER Jr, Ingram RH Jr. Parenteral vs. inhaled atropine: density dependence of maximal expiratory flow. J Appl Physiol 1982; 53: 392–6.
24. Holtzman MJ, McNamara MP, Sheppard D, et al. Intravenous versus inhaled atropine for inhibiting bronchoconstrictor responses in dogs. J Appl Physiol 1983; 54: 134–9.
25. Sheppard D, Epstein J, Holtzman MJ, Nadel JA, Boushey HA. Effect of route of atropine delivery on bronchospasm from cold air and methacholine. J Appl Physiol 1983; 54: 130–3.
26. Poppius H, Salorinne Y. Comparative trial of a new anticholinergic bronchodilator, Sch 1000, and salbutamol in chronic bronchitis. Br Med J 1973; 4: 134–6.
27. Hughes JA, Tobin MJ, Bellamy D, Hutchison DCS. Effects of ipratropium bromide and fenoterol aerosols in pulmonary emphysema. Thorax 1982; 37: 667–70.
28. Gross NJ, Skorodin MS. Role of the parasympathetic system in airway obstruction due to emphysema. N Engl J Med 1984; 311: 421–5.
29. Howarth PH. Durham SR, Lee TH, Kay AB, Church MK, Holgate ST. Influence of albuterol, cromolyn sodium and ipratropium bromide on the airway and circulating mediator responses to allergen bronchial provocation in asthma. Am Rev Respir Dis 1985; 132: 986–92.
30. Levine RM. The intestinal absorption of the quaternary derivatives of atropine and scopolamine. Arch Int Pharmacodyn Ther 1959; 121: 146–9.
31. Deckers W. The chemistry of new derivatives of tropane alkaloids and the pharmacokinetics of a new quaternary compound. Postgrad Med J 1975; 51: Suppl 7: 76–81.
32. Kalser SC. The fate of atropine in man. Ann NY Acad Sci 1971; 179: 667–83.
33. Weiner N. Atropine, scopolamine, and related antimuscarinic drugs. In: Oilman AG, Goodman LS, Gilman A, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980:120–37.
34. Madison JM, Jones CA, Tom-Moy M, Brown JK. Affinities of pirenzepine for muscarinic cholinergic receptors in membranes isolated from bovine tracheal mucosa and smooth muscle. Am Rev Respir Dis 1987; 135: 719–24.
35. Hammer K, Giachetti A. Muscarinic receptor subtypes: M1 and M2: biochemical and functional characterization. Life Sci 1983; 31: 2991–8.
36. Engelhardt A, Klupp H. The pharmacology and toxicology of a new tropane alkaloid derivative. Postgrad Med J 1975; 51: Suppl 7: 82–5.
37. Bauer R, Banholzer R, Griben C, et al. Ipratropium bromide. Pharmacol Biochem Prop Drug Subst 1979; 2: 489–515.
38. Storms WW, DoPico GA, Reed CE. Aerosol Sch 1000: an anticholinergic bronchodilator. Am Rev Respir Dis 1975; 111: 419–22.
39. Gross NJ. Sch 1000: a new anticholinergic bronchodilator. Am Rev Respir Dis 1975; 112: 823–8.
40. Yeager H Jr, Weinberg RM, Kaufman LV, Katz S. Asthma: comparative bronchodilator effects of ipratropium bromide and isoproterenol. J Clin Pharmacol 1976; 16: 198–204.
41. Allen CJ, Campbell AH. Dose response of ipratropium bromide assessed by two methods. Thorax 1980; 35: 137–9.
42. Gomm SA, Keaney NP, Hunt LP, Allen SC, Stretton TB. Dose–response comparison of ipratropium bromide from a metered-dose inhaler and by jet nebulisation. Thorax 1983; 38: 297–301.
43. Hockley B, Johnson NM. A comparison of three high doses of ipratropium bromide in chronic asthma. Br J Dis Chest 1985; 79: 379–84.
44. Dolovich MB, Sanchis J, Rossman C, Newhouse MT. Aerosol penetrance: a sensitive index of peripheral airways obstruction. J Appl Physiol 1976; 40: 468–71.
45. Pavia D, Thomson ML, Clark SW, Shannon HS. Effect of lung function and mode of inhalation on penetration of aerosol into the human lung. Thorax 1977; 32: 194–7.
46. Jenkins CR, Chow CM, Fisher BL, Marlin GE. Comparison of ipratropium bromide and salbutamol by aerosolized solution. Aust NZ J Med 1981; 11: 513–6.
47. Davis A, Vickerson F, Worsley G, Mindorff C, Kazim F, Levison H. Determination of dose–response relationship for nebulized ipratropium in asthmatic children. J Pediatr 1984; 105: 1002–5.
48. Ward MJ. Fentem PH. Smith WHR, Davies D. Ipratropium bromide in acute asthma. Br Med J 1981; 282: 598–600.
49. Ruffin RE, Newhouse MT. Ipratropium bromide (Sch 1000) monohydrate aerosol: bronchodilator effect of three dose levels in asthmatics. Lung 1978; 155: 141–6.
50. Tashkin DP, Ashutosh K, Bleecker ER, et al. Comparison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pulmonary disease: a 90-day multi-center study. Am J Med 1986; 81: Suppl 5A: 81–9.
51. Storms WW, Bodman SF, Nathan RA, et al. Use of ipratropium bromide in asthma: results of a multi-clinic study. Am J Med 1986; 81: Suppl 5A: 61–5.
52. Shifrin GS, Klein WL. Regulation of muscarinic acetylcholine receptor concentration in cloned neuroblastoma cells. J Neurochem 1980; 34: 993–9.
53. Newcomb R, Tashkin DP, Hui KK, Conolly ME, Lee E, Dauphinee B. Rebound hyperresponsiveness to muscarinic stimulation after chronic therapy with an inhaled antimuscarinic antagonist. Am Rev Respir Dis 1985; 132: 12–5.
54. Pakes GE, Brogden RN, Heel RC, Speight TM, Avery GS. Ipratropium bromide: a review of its pharmacological properties and therapeutic efficacy in asthma and chronic bronchitis. Drugs 1980; 20: 237–66.
55. Gross NJ, Skorodin MS. Anticholinergic, antimuscarinic bronchodilators. Am Rev Respir Dis 1984; 129: 856–70.
56. Gross NJ, Skorodin MS. Anticholinergic agents. In: Jenne JW, Murphy S, eds. Drug therapy for asthma: research and clinical practice. New York: Marcel Dekker, 1987:615–68.
57. Bergofsky EH, ed. Cholinergic pathway in obstructive airways disease. Am J Med 1986; 81: Suppl 5A: 1–102.
58. McFadden ER Jr. An analysis of exercise as a stimulus for the production of airway obstruction. Lung 1981; 159: 3–11.
59. Sheppard D, Epstein J, Holtzman MJ, Nadel JA, Boushey HA. Dose-dependent inhibition of cold air-induced bronchoconstriction by atropine. J Appl Physiol 1982; 53: 169–74.
60. Postma DS, Keyzer JJ, Koëter GH, Sluiter HJ, De Vries K. Influence of the parasympathetic and sympathetic nervous systems on nocturnal bronchial obstruction. Clin Sci 1985; 69: 251–8.
61. Barnes PJ. Circadian variation in airway function. Am J Med 1985; 79: Suppl 6A: 5–9.
62. Cox ID, Hughes DTD, McDonnell KA. Ipratropium bromide in patients with nocturnal asthma. Postgrad Med J 1984; 60: 526–8.
63. Coe CI, Barnes PJ. Reduction of nocturnal asthma by an inhaled anticholinergic drug. Chest 1986; 90: 485–8.
64. de Vries K. The protective effect of inhaled Sch 1000 MDI on bronchoconstriction induced by serotonin, histamine, acetylcholine and propranolol. Postgrad Med J 1975; 51: Suppl 7: 106. abstract.
65. Ind PW, Dixon CMS, Fuller RW, Barnes PJ. Anticholinergic blockade of propanolol induced bronchoconstriction. Thorax 1986; 41: 718. abstract.
66. McFadden ER Jr, Luparello T, Lyons HA, Bleecker E. The mechanism of action of suggestion in the induction of acute asthma attacks. Psychosom Med 1969; 31: 134–43.
67. Neild JE, Cameron IR. Bronchoconstriction in response to suggestion: its prevention by an inhaled anticholinergic agent. Br Med J 1985; 290: 674.
68. Rebuck AS, Marcus HI. SCH 1000 in psychogenic asthma. Scand J Respir Dis [Suppl] 1979; 103: 186–91.
69. Ruffin RE, Fitzgerald JD, Rebuck AS. A comparison of the bronchodilator activity of Sch 1000 and salbutamol. J Allergy Clin Immunol 1977; 59: 139–41.
70. Ullah MI, Newman GB, Saunders KB. Influence of age on response to ipratropium and salbutamol in asthma. Thorax 1981; 36: 523–9.
71. Burge PS, Harries MG, I'Anson E. Comparison of atropine with ipratropium bromide in patients with reversible airways obstruction unresponsive to salbutamol. Br J Dis Chest 1980; 74: 259–62.
72. Jolobe OMP. Reversible airflow obstruction: clinical spectrum and responsiveness to anticholinergic drugs. Respiration 1984; 45: 232–6.
73. Jolobe Asthma non-specific reversible airflow obstruction: clinical features and responsiveness to anticholinergic drugs. Respiration 1984; 45: 237–42.
74. Brown IG, Chan CS, Kelly CA, Dent AG, Zimmerman PV. Assessment of the clinical usefulness of nebulised ipratropium bromide in patients with chronic airflow limitation. Thorax 1984; 39: 272–6.
75. Anthonisen NR, Wright EC, IPPB Trial Group. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133: 814–9.
76. Gross NJ. COPD: a disease of reversible airflow obstruction. Am Rev Respir Dis 1986; 133: 725–6.
77. Lakshminarayan S. Ipratropium bromide in chronic bronchitis/emphysema: a review of the literature. Am J Med 1986; 81: Suppl 5A: 76–80.
78. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986; 315: 735–9.
79. Douglas NJ, Davidson I, Sudlow MF, Flenley DC. Bronchodilatation and the site of airflow resistance in severe chronic bronchitis. Thorax 1979; 34: 51–6.
80. Baigelman W, Chodosh S. Bronchodilator action of the anticholinergic drug, ipratropium bromide (Sch 1000), as an aerosol in chronic bronchitis and asthma. Chest 1977; 71: 324–8.
81. Marlin GE, Bush DE, Berend N. Comparison of ipratropium bromide and fenoterol in asthma and chronic bronchitis. Br J Clin Pharmacol 1978; 6: 547–9.
82. Lefcoe NM, Toogood JH, Blennerhassett G, Baskerville J, Paterson NAM. The addition of an aerosol anticholinergic to an oral beta agonist plus theophylline in asthma and bronchitis: a double-blind single dose study. Chest 1982; 82: 300–5.
83. De Troyer A, Yernault J-C, Rodenstein D. Effects of vagal blockade on lung mechanics in normal man. J Appl Physiol 1979; 46: 217–26.
84. Lulling J, Delwiche JP, Ledent C, Prignot J. Controlled trial of the effect of repeated administration of ipratropium bromide on ventilatory function of patients with severe chronic airways obstruction. Br J Dis Chest 1980; 74: 135–41.
85. Leitch AG. Hopkin JM, Ellis DA, Merchant S, McHardy GJR. The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax 1978; 33: 711–3.
86. Ward MJ, Fentem PH, Smith WHR, Davies D. Ipratropium bromide in acute asthma. Br Med J 1981; 282: 598–600.
87. Leahy BC, Gomm SA, Allen SC. Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma. Br J Dis Chest 1983; 77: 159–63.
88. Bryant DH. Nebulized ipratropium bromide in the treatment of acute asthma. Chest 1985; 88: 24–9.
89. Ward MJ, Macfarlane JT, Davies D. A place for ipratropium bromide in the treatment of severe acute asthma. Br J Dis Chest 1985; 79: 374–8.
90. Beck R, Robertson C, Galdès-Sebaldt M, Levison H. Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. J Pediatr 1985; 107: 605–8.
91. McGivern DV, Fentem PH, MacFarlane JT, Davies D. Responses to the sequential administration of salbutamol and ipratropium bromide during recovery from acute severe asthma. Thorax 1984; 39: 227–8. abstract.
92. Rebuck AS, Chapman KR, Abboud R, et al. Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987; 82: 59–64.
93. Backman R, Hellström P-E. Fenoterol and ipratropium bromide in respirator treatment of patients with chronic bronchitis. Curr Ther Res 1985; 38: 135–40.
94. Chervinsky P. Concomitant bronchodilator therapy and ipratropium bromide: a clinical review. Am J Med 1986; 81: Suppl 5A: 67–72.
95. Bruderman I, Cohen-Aronovski R. Smorzik J. A comparative study of various combinations of ipratropium bromide and metaproterenol in allergic asthmatic patients. Chest 1983; 83: 208–10.
96. Yeates DB, Aspin N, Levison H. Jones MT, Bryan achéal. Mucociliary tracheal transport rates in man. J Appl Physiol 1975; 39: 487–95.
97. Wanner A. Effect of ipratropium bromide on airway mucociliary function. Am J Med 1986; 81: Suppl 5A: 23–7.
98. Konietzko N, Müller N, Adam WE. Matthys H. Untersuchungen zur mukociliaren Clearance nach Anwendung von Atrovent® bei Gesunden und Patienten mit chronischer Bronchitis. Wien Med Wochenschr 1974; 124: Suppl 21: 15–9.
99. Francis RA, Thomson ML, Pavia D, Douglas RB. Ipratropium bromide: mucociliary clearance rate and airway resistance in normal subjects. Br J Dis Chest 1977; 71: 173–8.
100. Ruffin RE, Wolff RK, Dolovich MB, Rossman CM, Fitzgerald JD, New-house MT. Aerosol therapy with Sch 1000: short-term mucociliary clearance in normal and bronchitic subjects and toxicology in normal subjects. Chest 1978; 73: 501–6.
101. Pavia D. Bateman JRM, Sheahan NF, Clarke SW. Effect of ipratropium bromide on mucociliary clearance and pulmonary function in reversible airways obstruction. Thorax 1979; 34: 501–7.
102. Pavia Clearance of lung secretions in patients with chronic bronchitis: effect of terbutaline and ipratropium bromide aerosols. Eur J Respir Dis 1980; 61: 245–53.
103. Foster WM, Bergofsky EH. Airway mucus membrane: effects of beta-adrenergic and anticholinergic stimulation. Am J Med 1986; 81: Suppl 5A: 28–35.
104. Bell JA, Bluestein BM, Danta I, Wanner A. Effect of inhaled ipratropium bromide on tracheal mucociliary transport in bronchial asthma. Mt Sinai J Med (NY) 1984; 51: 215–7.
105. Chervinsky P. Double-blind study of ipratropium bromide, a new anticholinergic bronchodilator. J Allergy Clin Immunol 1977; 59: 22–30.
106. Fasske E, Jüngst G, Themann H. Light and electron microscopic studies of human bronchial epithelium following treatment with Sch 1000 metered dose inhaler (MDI). Postgrad Med J 1975; 51: Suppl 7: 107. abstract.
107. Scheufler G. Ophthalmotonometry, pupil diameter and visual accommodation following repeated administration of Sch 1000 MDI in patients with glaucoma. Postgrad Med J 1975; 51: Suppl 7: 132. abstract.
108. Thumm HW. Ophthalmic effects of high doses of Sch 1000 MDI in healthy volunteers and patients with glaucoma. Postgrad Med J 1975; 51: Suppl 7: 132–3. abstract.
109. The effects of long-term treatment with SCH 1000 MDI. Postgrad Med J 1975; 51: Suppl 7: 130–4. abstracts.
110. Molkenboer JFWM, Lardenoye JG. The effect of Atrovent in micturition function, double blind cross-over study. Scand J Respir Dis [Suppl] 1979; 103: 154–8.
111. Field GB. The effects of posture, oxygen, isoproterenol and atropine on ventilation-perfusion relationships in the lung in asthma. Clin Sci 1967; 32: 279–88.
112. Gross NJ, Bankwala Z. Effects of an anticholinergic bronchodilator on arterial blood gases of hypoxemic patients with chronic obstructive pulmonary disease: comparison with a beta-adrenergic agent. Am Rev Respir Dis 1987; 136: 1091–4.
113. Anderson WM. Hemodynamic and non-bronchial effects of ipratropium bromide. Am J Med 1986; 81: Suppl 5A: 45–52.
114. Sackner MA, Friedman M, Silva G, Fernandez R. The pulmonary hemodynamic effects of aerosols of isoproterenol and ipratropium in normal subjects and patients with reversible airway obstruction. Am Rev Respir Dis 1977; 116: 1013–22.
115. Ravez P, Richez M, Halloy J-L, Robience Y. Haemodynamic variables in chronic obstructive airways diseases: the influence of fenoterol and ipratropium bromide. Clin Trials J 1979; 16: 147–51.
116. Chapman KR, Smith DL, Rebuck AS, Leenen FHH. Hemodynamic effects of inhaled ipratropium bromide, alone and combined with an inhaled beta2-agonist. Am Rev Respir Dis 1985; 132: 845–7.
117. Connolly CK. Adverse reaction to ipratropium bromide. Br Med J 1982; 285: 934–5.
118. Patel KR, Tullett WM. Bronchoconstriction in response to ipratropium bromide. Br Med J 1983; 286: 1318.
119. Mann JS, Howarth PH. Holgate ST. Bronchoconstriction induced by ipratropium bromide in asthma: relation to hypotonicity. Br Med J 1984; 289: 469.